TGFBR1*6A Allele Linked to Fewer Polyps and Lower Colorectal Cancer Incidence in Mouse Models and Family Registry Data

Researchers replaced murine Tgfbr1 exon 1 with the human TGFBR16A sequence, creating a knock-in model that exhibited measurably fewer intestinal polyps and adenocarcinomas than wild-type littermates. Parallel analysis of registry families found lower colorectal cancer incidence among carriers, with the effect size largest in siblings of affected probands and in individuals with familial adenomatous polyposis. Earlier genome-wide arrays and standard NGS pipelines systematically missed the variant because of repetitive sequence context around exon 1. The finding reframes TGFBR16A from a suspected risk allele, first flagged in the late 1990s, to a protective factor that attenuates TGF-beta signaling. This is consistent with observational data showing that partial pathway attenuation can limit early neoplastic growth while preserving later tumor-suppressor functions, a pattern also noted in SMAD4 dosage studies. Population-level impact could be meaningful given the allele frequency, yet absolute risk differences remain unquantified. Next steps require prospective cohort validation with long-read sequencing to capture the variant accurately, followed by functional assays that quantify signaling thresholds separating protection from progression. Without randomized evidence or mechanistic dosing data, clinical translation stays speculative.